Cencora, Inc. (COR)
Automate Your Wheel Strategy on COR
With Tiblio's Option Bot, you can configure your own wheel strategy including COR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COR
- Rev/Share 1633.9741
- Book/Share 11.4033
- PB 28.298
- Debt/Equity 4.1615
- CurrentRatio 0.9047
- ROIC 0.1006
- MktCap 56059823700.0
- FreeCF/Share 5.8907
- PFCF 49.1068
- PE 29.5351
- Debt/Assets 0.1114
- DivYield 0.0075
- ROE 1.9632
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | COR | Wells Fargo | Equal Weight | Overweight | -- | $337 | June 3, 2025 |
| Resumed | COR | Mizuho | -- | Outperform | -- | $280 | Dec. 4, 2024 |
| Downgrade | COR | BofA Securities | Buy | Neutral | $275 | $245 | Sept. 18, 2024 |
News
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Read More
Cencora (COR) is a Top-Ranked Growth Stock: Should You Buy?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
3 Medical Services Industry Stocks to Buy as AI Fuels Growth
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Medical - Services industry is undergoing a transformation on massive artificial intelligence adoption. COR, DOCS and MD are set to gain the most.
Read More
Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here is Why Growth Investors Should Buy Cencora (COR) Now
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Here's Why You Should Add Cencora Stock to Your Portfolio Now
Published: March 11, 2025 by: Zacks Investment Research
Sentiment: Positive
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Read More
Why Is Cencora (COR) Up 3.1% Since Last Earnings Report?
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
Read More
Scoop Up These 3 GARP Stocks to Receive Handsome Returns
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. SFM, COR and AXP are some stocks that hold promise.
Read More
3 Reasons Why Growth Investors Shouldn't Overlook Cencora (COR)
Published: February 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Read More
Cencora: Higher Potential Returns After Reduced Walgreens Stake
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ credit rating, and an active share repurchase program, enhancing shareholder returns. Strategic acquisitions like Retina Consultants of America position Cencora for long-term success, with management guiding for 10% annual EPS growth.
Read More
3 GARP Stocks That Investors Can Scoop Up for Maximum Returns
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. AXP, COR and TPX hold promise.
Read More
About Cencora, Inc. (COR)
- IPO Date 1995-04-04
- Website https://www.amerisourcebergen.com
- Industry Medical - Distribution
- CEO Robert P. Mauch PharmD
- Employees 42000